Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dermatomyositis after interferon alpha treatment.

L L Dietrich1, A J Bridges, M R Albertini

  • 1Department of Internal Medicine, Section of Medical Oncology, University of Wisconsin, Madison, Wisconsin, USA.

Medical Oncology (Northwood, London, England)
|March 14, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracellular patterns of sialophorin expression define a new molecular classification of breast cancer and represent new targets for therapy.

British journal of cancer·2013
Same author

Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial.

Cancer gene therapy·2007
Same author

Therapeutic challenges of kinase and phosphatase inhibition and use in anti-diabetic strategy.

Biochemical Society transactions·2005
Same author

Chemical inhibitors of protein kinases.

Chemical reviews·2001
Same author

Donor-derived small cell lung carcinoma in a kidney transplant recipient.

Cancer·2001
Same author

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.

Journal of medicinal chemistry·2001

High-dose interferon (IFN) therapy, used for melanoma, may trigger autoimmune diseases like dermatomyositis. This first-time report highlights the need to recognize IFN-associated autoimmune conditions for accurate diagnosis and patient care.

Area of Science:

  • Immunology
  • Oncology
  • Dermatology

Background:

  • Interferon (IFN) has been linked to autoimmune disorders, with elevated IFNalpha levels correlating with disease activity in patients.
  • IFNalpha treatment in humans has been associated with the development of various autoimmune phenomena.

Observation:

  • A patient with regionally metastatic melanoma received adjuvant high-dose interferon alfa-2b (IFNalpha2b) post-surgery.
  • Following treatment, the patient developed dermatomyositis, a rare autoimmune condition.

Findings:

  • This case represents the first documented instance of dermatomyositis developing in association with interferon alfa treatment.
  • A review of existing literature supports a connection between IFNalpha and autoimmune diseases, suggesting potential contributing mechanisms.

Related Experiment Videos

Implications:

  • High-dose IFNalpha2b is increasingly used for adjuvant melanoma treatment, raising clinical concerns about potential IFN-associated autoimmune diseases.
  • The similarity between standard IFN therapy side effects and autoimmune symptoms necessitates careful diagnosis to identify conditions like dermatomyositis.
  • Recognizing dermatomyositis as a potential side effect of high-dose IFNalpha is crucial for effective patient management and treatment.